Part I/II of MRC’s Critique of Amarin’s Assertions of Inducement and Non-Obviousness in its Proposed..
Summary:Update on section 1.6 from our greater report, entitled "AMRN: Market Headwinds and Inherent..
Summary:Legal analysis on inducement and prior art relevant to Amarin v. Dr Reddy's Labs/Hikma Pharm..
AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP
Since having ..
Showing 1 to 4 of 4 (1 Pages)